Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;40(3):2097-105.
doi: 10.1007/s11033-012-2268-6. Epub 2012 Dec 7.

Disruption of the transcription factor RBP-J results in osteopenia attributable to attenuated osteoclast differentiation

Affiliations

Disruption of the transcription factor RBP-J results in osteopenia attributable to attenuated osteoclast differentiation

Jing Ma et al. Mol Biol Rep. 2013 Mar.

Abstract

The transcription factor recombination signal binding protein-Jκ (RBP-J) is the critical transcription factor downstream to all four mammalian Notch receptors. Although it has been reported that Notch signaling pathway is involved in bone remodeling, the importance of RBP-J in osteoclastogenesis has not been fully explored. To investigate the role of RBP-J in osteoclastogenesis, we conditionally deleted RBP-J systemically in bone marrow (BM) or specifically in macrophages. We found that disruption of RBP-J in BM resulted in an obvious decrease in trabecular bone mass associated with an increase in osteoclasts, leading to osteopenia. Disruption of RBP-J in macrophages phenocopied the phenotypes of RBP-J deletion in BM with respect to osteoclastogenesis, suggesting that the osteopenia in RBP-J deficient mice is essentially resulted from increased osteoclastogenesis. Furthermore, we found that RBP-J deletion in osteoclasts resulted in a dramatic increase in tartrate-resistant acid phosphatase expression. These findings demonstrate a negatively role of RBP-J in the differentiation of osteoclasts and suggest that Notch pathway may be a new therapeutic target for bone diseases related to increased osteoclastogenesis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nature. 2003 May 15;423(6937):337-42 - PubMed
    1. J Biol Chem. 1999 Aug 13;274(33):22907-10 - PubMed
    1. Nat Immunol. 2012 May 20;13(7):642-50 - PubMed
    1. Nature. 1990 May 31;345(6274):442-4 - PubMed
    1. Immunol Rev. 2005 Dec;208:126-40 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources